
    
      The primary goal of this trial is to assess the activity, safety, and tolerability of
      tisotumab vedotin for the treatment of selected solid tumors. Patients will be treated with
      single agent tisotumab vedotin. Patients who meet eligibility criteria will be enrolled into
      cohorts based on tumor type. Tumor types to be evaluated include colorectal cancer, squamous
      non-small cell lung cancer (NSCLC), exocrine pancreatic adenocarcinoma, and squamous cell
      carcinoma of the head and neck (SCCHN).
    
  